Category: Uncategorized

 

AIBILI wishes you a joyous Holiday Season and a prosperous New Year!

The Centre for Health Technology Assessment and Drug Research of AIBILI will organize on December 13, 2019 the first meeting of the Drug Safety and Effectiveness Research Network. Please check here the programme and how to register.

Programa: AIBILI Workshop DruSER.Net

AIBILI was present at the EATRIS – European Infrastructure for translational Medicine, National Hub Kick off Meeting, at INFARMED, Lisbon.

In this meeting, which counted with the presence of EATRIS international representatives and EATRIS-integrating Portuguese institutes, AIBILI presented it capacities, technologies and infrastructures that were fundamental to be part of this European Network.

 

To learn more about EATRIS, visit the network website https://eatris.eu/

Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de várias questões relacionadas com a segurança de metotrexato, fingolimod, montelucaste, terapia hormonal de substituição, febuxostate, tocilizumab, lisados bacterianos e paclitaxel e sobre a retirada do mercado de lotes de Goserrelina Teva®. São ainda apresentadas as atividades científicas e os resultados das atividades da Unidade de Farmacovigilância de Coimbra (UFC), referentes ao terceiro trimestre de 2019.

Farmacovigilância: Atualizações de segurança de medicamentos – Vol. 6, Nº 3 – 3º Trimestre . Consulte: Farmacovigilância – Atualizações de segurança de medicamentos Vol 6N 3

We are pleased to announce our latest publication on RetmarkerAMD® validation, published in the Eye newspaper, a Springer Nature group and official publication of the UK College of Ophthalmologists.

By conducting a carefully planned multicentre, cross-sectional study, we were able to demonstrate that RetmarkerAMD® is a reliable and consistent semiautomated classification tool for Age-related Macular Degeneration, which may be used both in clinical studies and in clinical trials.

RetmarkerAMD® is a software developed by the Retmaker company in partnership with AIBILI that facilitates the marking and counting of Age-related Macular Degeneration (AMD) lesions. It was initially developed for the epidemiological Coimbra Eye Study and has since been used in several other studies.

Journal Reference:

https://www.nature.com/articles/s41433-019-0624-7

AIBILI was represented by Diogo Mendes at the 19^th Annual Meeting of the ISoP International Society of Pharmacovigilance, in Bogotá (Colombia, October 26 to 29).

AIBILI organized in the EVICR.net annual Members Meeting, on October 24 and 25, at Infarmed (Lisbon) that was attended by about 100 participants who had the opportunity to update on the activities in the different subspecialty areas to network and discuss new clinical study ideas and EU applications.

Members of CHAD team were present on the 8^th Pharmacovigilance Seminar of Spanish Pharmacovigilance System for Medicinal Products for Human Use, took place in Tordesillas, Spain, on October 23-25. This was the first time the meeting was held in a joint organization with the Portuguese Pharmacovigilance System.

Farmacovigilância: Atualizações de segurança de medicamentos – Vol. 6, Nº 2 – 2º Trimestre . Consulte: Farmacovigilância – Atualizações de segurança de medicamentos Vol 6N 2

AIBILI was present at TECH@PORTUGAL, on the 4th of July at Alfândega do Porto, an event that presented the best Portuguese innovation and technology.

We would like to thank to our partner Retmarker to the support, and to ANI – Agência Nacional de Inovação for the invitation!